From Scorpion Venom to Infection Research: The Promise of Opis16a
A synthetic peptide inspired by a southern African scorpion’s venom shows activity against drug-resistant bacteria—but its potential as a wound treatment remains under investigation.
Scorpion venom is a complex mixture of biologically active molecules. While many are studied for their effects on ion channels and the nervous system, others offer a different research opportunity: understanding how peptides can damage bacterial cells.
One such candidate is Opis16a, a synthetic, 16-amino-acid fragment derived from opistoporin 1, a peptide originally isolated from the venom of Opistophthalmus carinatus. Research highlighted by Nature Africa suggests that this shortened molecule combines broad antibacterial activity with relatively low toxicity in preliminary laboratory testing.
Finding a promising fragment
Researchers at the University of Pretoria evaluated 116 antimicrobial peptides reported from African wildlife, including scorpions, frogs, ticks, and primates. Using published evidence and computational predictions, they narrowed the selection to 46 candidates, prioritizing less extensively studied molecules and shorter sequences that could simplify manufacturing.
Among the candidates were two synthetic fragments of the 44-amino-acid opistoporin 1: Opis16a and the eight-amino-acid Opis8a.
Their performance differed sharply. Opis16a inhibited all 12 bacterial strains in the screening, whereas Opis8a showed no detectable antibacterial activity. The comparison illustrates an important principle in peptide development: shortening a molecule can preserve useful activity, but removing too much can eliminate the features that make it effective.
Four candidates acted against all 12 strains at relatively low concentrations. Opis16a stood out because it also showed very little toxicity in the mammalian-cell screening.
How does it attack bacteria?
Opis16a’s positive charge helps it interact with negatively charged bacterial surfaces. In Gram-negative bacteria, it interacts with the outer membrane before disrupting the inner membrane.
Tests involving Acinetobacter baumannii, a bacterium associated with serious hospital infections, showed substantial membrane damage and bacterial killing within approximately 15 minutes at higher tested concentrations.
This mechanism makes Opis16a interesting for antimicrobial research. However, membrane disruption does not make resistance impossible. Bacteria can modify their surface charge or membrane composition in ways that reduce a peptide’s effectiveness.
Encouraging results in an early infection model
The researchers also tested Opis16a in wax-moth larvae, Galleria mellonella, infected with multidrug-resistant A. baumannii.
At a dose of 10 milligrams per kilogram, survival was 87% among larvae receiving Opis16a and 83% among those receiving polymyxin B at the same dose. These findings support further investigation, but the numerical difference alone does not establish that the peptide is superior to the antibiotic.
An insect model provides an early indication of activity within a living organism. It cannot establish safety or effectiveness in humans.
The challenge inside a wound
A wound presents conditions that are much more complicated than a laboratory culture. Enzymes, proteins, and other components of wound fluid may degrade peptides or interfere with their activity.
Opis16a retained antibacterial activity in 20% foetal calf serum but lost activity after exposure to trypsin, a protein-cleaving enzyme. Its stability under realistic wound conditions therefore remains an essential question.
The peptide also caused no detectable haemolysis—destruction of human red blood cells—at the concentrations tested and showed relatively low toxicity in the mammalian cell lines examined. These are encouraging findings, but further safety testing and more advanced infection models are needed.
Why this matters
For venom research, Opis16a demonstrates how a naturally occurring molecule can guide the design of a smaller synthetic candidate. Its promise depends on the particular amino acids retained and how their arrangement influences interactions with bacterial and mammalian cells.
Opis16a remains an experimental research candidate. Whether it can become a useful wound treatment will depend on its stability, safety, effectiveness in more realistic biological systems, and practical manufacturing costs.
For now, it offers another compelling example of how studying scorpion venom can reveal molecular starting points for antimicrobial discovery.
Sources
Original research:
van der Walt, M., Oosthuizen, C. B., Mason, A. J., et al. (2026). Scorpion venom-derived Opis16a shows potent membrane-destabilising Gram-negative activity and promising in vivo topical efficacy. npj Antimicrobial Resistance. https://doi.org/10.1038/s44259-026-00266-9
Related coverage:
Nature Africa’s report on Opis16a and drug-resistant wound infections.